Semaglutide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 20 registered trials.

Also followed for narrower conditions: Pediatric Obesity

Why this status

  1. 4 Jun 2018: Trial started, NCT03548935
  2. 4 Jun 2018: Trial started, NCT03552757
  3. 7 Jun 2018: Trial registered, NCT03548935
  4. 12 Jun 2018: Trial registered, NCT03552757
  5. 2 Jul 2018: Trial registered, NCT03574597
  6. 1 Aug 2018: Trial started, NCT03611582
  7. 2 Aug 2018: Trial registered, NCT03611582
  8. 3 Oct 2018: Trial registered, NCT03693430
  9. 5 Oct 2018: Trial started, NCT03693430
  10. 24 Oct 2018: Trial started, NCT03574597
  11. 9 Mar 2021: Trial registered, NCT04788511
  12. 16 Mar 2021: Trial started, NCT04788511
  13. 6 Sep 2021: Trial started, NCT05040971
  14. 10 Sep 2021: Trial registered, NCT05040971
  15. 27 Jan 2023: Trial registered, NCT05702905
  16. 27 Mar 2023: Trial registered, NCT05786521
  17. 1 Apr 2023: Trial started, NCT05786521
  18. 19 Apr 2023: Trial registered, NCT05819853
  19. 29 Apr 2023: Trial started, NCT05870462
  20. 9 May 2023: Trial started, NCT05702905
  21. 23 May 2023: Trial registered, NCT05870462
  22. 3 Nov 2023: Trial started, NCT05819853
  23. 10 Dec 2025: Trial registered, NCT07275697
  24. 23 Mar 2026: Trial started, NCT07275697
  25. 18 May 2026: Trial registered, NCT07592546
  26. 21 Oct 2026: Trial started, NCT07592546

The trials

NCT03548935: STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

State
Completed
Phase
Phase 3
People
1,961 taking part
Started
4 Jun 2018
Primary completion
30 Mar 2020
Arms
Semaglutide s.c. 2.4 mg once weekly
Results
Posted on the registry
  1. 4 Jun 2018: Trial started
  2. 7 Jun 2018: Trial registered
  3. 5 Mar 2021: Trial completed
  4. 11 Aug 2021: Trial results posted

NCT03552757: Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

State
Completed
Phase
Phase 3
People
1,210 taking part
Started
4 Jun 2018
Primary completion
24 Mar 2020
Arms
Semaglutide 1.0 mg, Semaglutide 2.4 mg
Results
Posted on the registry
  1. 4 Jun 2018: Trial started
  2. 12 Jun 2018: Trial registered
  3. 1 May 2020: Trial completed
  4. 11 Aug 2021: Trial results posted

NCT03574597: Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

State
Completed
Phase
Phase 3
People
17,604 taking part
Started
24 Oct 2018
Primary completion
21 Jun 2023
Arms
Semaglutide
Results
Posted on the registry
  1. 2 Jul 2018: Trial registered
  2. 24 Oct 2018: Trial started
  3. 29 Jun 2023: Trial completed
  4. 30 Aug 2024: Trial results posted

NCT03611582: Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

State
Completed
Phase
Phase 3
People
611 taking part
Started
1 Aug 2018
Primary completion
18 Mar 2020
Arms
Semaglutide
Results
Posted on the registry
  1. 1 Aug 2018: Trial started
  2. 2 Aug 2018: Trial registered
  3. 28 Apr 2020: Trial completed
  4. 9 Jul 2021: Trial results posted

NCT03693430: Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

State
Completed
Phase
Phase 3
People
304 taking part
Started
5 Oct 2018
Primary completion
29 Jan 2021
Arms
Semaglutide
Results
Posted on the registry
  1. 3 Oct 2018: Trial registered
  2. 5 Oct 2018: Trial started
  3. 23 Mar 2021: Trial completed
  4. 23 Mar 2022: Trial results posted

NCT04788511: Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

State
Completed
Phase
Phase 3
People
529 taking part
Started
16 Mar 2021
Primary completion
18 Apr 2023
Arms
Semaglutide
Results
Posted on the registry
  1. 9 Mar 2021: Trial registered
  2. 16 Mar 2021: Trial started
  3. 18 Apr 2023: Trial completed
  4. 11 Jun 2024: Trial results posted

NCT05040971: Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes

State
Completed
Phase
Phase 3
People
207 taking part
Started
6 Sep 2021
Primary completion
6 Jan 2023
Arms
Semaglutide
Results
Posted on the registry
  1. 6 Sep 2021: Trial started
  2. 10 Sep 2021: Trial registered
  3. 14 Jul 2023: Trial completed
  4. 28 Oct 2024: Trial results posted

NCT05302596: Semaglutide Use in Elderly Obese Patients

State
Completed
Phase
Phase 2
People
16 taking part
Started
1 Sep 2022
Primary completion
23 Oct 2023
Arms
Semaglutide
Results
Posted on the registry
  1. 31 Mar 2022: Trial registered
  2. 1 Sep 2022: Trial started
  3. 30 Oct 2024: Trial completed
  4. 17 Apr 2025: Trial results posted

NCT05616013: Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

State
Completed
Phase
Phase 2
People
507 taking part
Started
16 Nov 2022
Primary completion
16 May 2024
Arms
Placebo + 1.0 mg Semaglutide, Placebo + 2.4 mg Semaglutide
Results
Posted on the registry
  1. 14 Nov 2022: Trial registered
  2. 16 Nov 2022: Trial started
  3. 14 Jun 2025: Trial completed
  4. 18 Jul 2025: Trial results posted

NCT05702905: Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

State
State not given
Phase
Phase 4
People
75 planned
Started
9 May 2023
Primary completion
31 Dec 2024
Arms
semaglutide
Results
None posted
Papers
doi:10.1007/bf03401383, doi:10.1007/s00404-022-06700-3, doi:10.1007/s40618-021-01666-6, doi:10.1016/j.rbmo.2019.04.017, doi:10.1097/cm9.0000000000001712, doi:10.1111/cen.13454, doi:10.1210/clinem/dgaa285, doi:10.1530/eje-13-0797, doi:10.1530/eje-18-0175, doi:10.17219/acem/151695, doi:10.3389/fendo.2022.945609
  1. 27 Jan 2023: Trial registered
  2. 9 May 2023: Trial started

NCT05746039: Feasibility of Semaglutide in Advanced Lung Disease

State
Under way
Phase
Phase 1 and Phase 2
People
8 planned
Started
29 Jan 2024
Primary completion
28 Dec 2027
Arms
Study Drug (semaglutide)
Results
None posted
  1. 27 Feb 2023: Trial registered
  2. 29 Jan 2024: Trial started

NCT05786521: Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

State
Completed
Phase
Phase 4
People
20 taking part
Started
1 Apr 2023
Primary completion
20 May 2024
Arms
Semaglutide and lifestyle intervention
Results
Posted on the registry
  1. 27 Mar 2023: Trial registered
  2. 1 Apr 2023: Trial started
  3. 20 May 2024: Trial completed
  4. 4 May 2025: Trial results posted

NCT05819853: Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

State
Under way
Phase
Phase 3
People
80 planned
Started
3 Nov 2023
Primary completion
1 Feb 2028
Arms
Untreated PCOS, PCOS on Metformin
Results
None posted
  1. 19 Apr 2023: Trial registered
  2. 3 Nov 2023: Trial started

NCT05870462: Semaglutide and Vascular Regeneration

State
State not given
Phase
Phase 4
People
100 planned
Started
29 Apr 2023
Primary completion
Dec 2024
Arms
Semaglutide
Results
None posted
  1. 29 Apr 2023: Trial started
  2. 23 May 2023: Trial registered

NCT06131372: A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

State
Completed
Phase
Phase 2
People
626 taking part
Started
1 Apr 2024
Primary completion
24 Sep 2025
Arms
Semaglutide
Results
None posted
  1. 14 Nov 2023: Trial registered
  2. 1 Apr 2024: Trial started
  3. 6 Nov 2025: Trial completed

NCT06173778: Semaglutide for Post-Smoking Cessation Weight Management

State
Under way
Phase
Phase 2
People
197 planned
Started
23 Apr 2024
Primary completion
25 May 2028
Arms
semaglutide
Results
None posted
  1. 18 Dec 2023: Trial registered
  2. 23 Apr 2024: Trial started

NCT06411210: Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

State
Under way
Phase
Phase 2
People
54 planned
Started
16 Jul 2024
Primary completion
30 Apr 2028
Arms
Semaglutide
Results
None posted
  1. 13 May 2024: Trial registered
  2. 16 Jul 2024: Trial started

NCT07275697: Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study

State
Under way
Phase
Phase 4
People
200 planned
Started
23 Mar 2026
Primary completion
30 Dec 2028
Arms
Randomized to Semaglutide
Results
None posted
  1. 10 Dec 2025: Trial registered
  2. 23 Mar 2026: Trial started

NCT07592546: Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss

State
Under way
Phase
Phase 4
People
240 planned
Started
21 Oct 2026
Primary completion
1 Dec 2028
Arms
Overweight Group (BMI 27 - 40 kg/m2)
Results
None posted
  1. 18 May 2026: Trial registered
  2. 21 Oct 2026: Trial started

NCT07909889: Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer

State
Not started
Phase
Phase 2
People
32 planned
Started
Mar 2027
Primary completion
Mar 2029
Arms
Immediate-start semaglutide, Delayed-start semaglutide
Results
None posted
  1. 2 Nov 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Arm 2 - DehydraTECH-semaglutide alone, Ozempic, Rybelsus, Semaglutide (Wegovy®), Semaglutide 1.0 mg, Semaglutide 2.4 mg, Semaglutide Injectable Product, Semaglutide Injectable Product (Wegovy and/or Ozempic), Semaglutide Pen Injector, Semaglutide, 1.34 mg/mL, Wegovy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.